Waist to Height Ratio Is an Independent Predictor for the Incidence of Chronic Kidney Disease

Keiichi Odagiri1*, Isagi Mizuta2, Makoto Yamamoto2, Yosuke Miyazaki3, Hiroshi Watanabe1, Akihiko Uehara2

1 Department of Clinical Pharmacology and Therapeutics, Hamamatsu University School of Medicine, Higashi-ku, Hamamatsu, Japan, 2 Yamaha Health Care Center, Naka-ku, Hamamatsu, Japan, 3 Department of Mental Health, Institute of Industrial Ecological Sciences, School of Medicine, University of Occupational and Environmental Health, Yahatanishi-ku, Kitakyushu, Japan

Abstract

Objective: Obesity is a risk factor for chronic kidney disease (CKD) and cardiovascular disease. The association between waist to height ratio (WheiR) and CKD is unclear. This study evaluated the association between WheiR and CKD.

Design and Methods: In this longitudinal cohort study, 4841 Japanese workers (3686 males, 1155 females) 18 to 67 years of age in 2008 were followed up until 2011. CKD was defined as an estimated glomerular filtration rate of <60 mL/min/1.73 m² (by the Modification of Diet in Renal Disease equation for Japanese) or dipstick proteinuria (≥1+). Cox proportional hazards models were used to examine the relationship between WheiR and development of CKD.

Results: A total of 384 (7.9%) participants (300 men and 84 women) were found to have new CKD. The incidence of CKD was 13.7, 24.2, 37.9 and 43.7 per 1000 person-years of follow-up in the lowest, second, third and highest quartiles of WheiR, respectively. After adjustment for potential confounders, the adjusted hazard ratios (95% confidence interval) for CKD were 1.00 (reference), 1.23 (0.85, 1.78), 1.59 (1.11, 2.26) and 1.62 (1.13, 2.32) through the quartiles of WheiR, respectively. WheiR had a significant predictive value for the incidence of both proteinuria and low estimated glomerular filtration rate. After subdivision according to gender, the relationship between WheiR and the incidence of CKD was statistically significant in the unadjusted model. However, after adjusting for potential confounders, WheiR was significantly associated with the incidence of CKD in females, whereas it was not significant in males.

Conclusions: WheiR, which is commonly used as an index of central obesity, is associated with CKD. There was a significant gender difference in the relationship between WheiR and CKD.

Citation: Odagiri K, Mizuta I, Yamamoto M, Miyazaki Y, Watanabe H, et al. (2014) Waist to Height Ratio Is an Independent Predictor for the Incidence of Chronic Kidney Disease. PLoS ONE 9(2): e88873. doi:10.1371/journal.pone.0088873

Editor: Giuseppe Danilo Norata, University of Milan, Italy

Received September 2, 2013; Accepted January 14, 2014; Published February 12, 2014

Copyright: © 2014 Odagiri et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: Hiroshi Watanabe received research funding from the Ministry of Health, Labour and Welfare of Japan, Teika Seiyaku, Takeda Pharmaceuticals, Mochida, Pfizer, Astellas Pharmaceuticals, and Daiichi Sankyo. The commercial funding is not specifically related to the study, and there are no other current external funding sources for this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: Hiroshi Watanabe has received lecture fees from Pfizer, Acterion, Novartis, Daiichi Sankyo, GlaxoSmithKline and Nippon Shinyaku. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.

* E-mail: kodagiri@hama-med.ac.jp

Introduction

Chronic kidney disease (CKD) is a relatively common disorder. Patients with CKD have an increased risk of end-stage renal disease. Furthermore, CKD is also related to both a higher prevalence of cardiovascular disease and premature death [1,2]. The estimated proportion of patients with CKD in the general population is approximately 10% in the United States, 7% in the United Kingdom, 9–10% in Asian countries and 19% in Japan [3–7]. The prevalence of CKD has been increasing significantly with time [8,9]. Therefore, screening, diagnosis and treatment of CKD are important issues in preventing disease onset and progression [10,11].

A recent study reported that obesity is a primary risk factor for cardiovascular disease, diabetes mellitus, hypertension and metabolic syndrome, and that these risk factors are associated with CKD [12]. Many authors consider that abdominal obesity is superior to body mass index (BMI) in predicting cardiometabolic risk, and visceral fat is known to have high metabolic and inflammatory activity in comparison to subcutaneous fat [13–17]. Waist to height ratio (WheiR) is recognized as an effective index for identifying central obesity, which relates to cardiometabolic risk factors [18]. One meta-analysis has demonstrated that WheiR is statistically superior to both waist circumference (WC) and BMI in the evaluation of cardiometabolic risk [19]. However, few studies have demonstrated an association between WheiR and CKD. Thus, we hypothesized that WheiR was associated with the incidence of CKD. We tested this hypothesis by investigating the 3-year incidence of CKD in Japanese workers.

Materials and Methods

Ethics Statement

The Institutional Review Board waived the need for informed consent from the participants because this research was a...
rare, sometimes, everyday), regular exercise habit (exercising at
(never, former or current smoker), alcohol drinking behavior (non/
lifestyle factors and medical history, including smoking status
fill out a self-administered standardized questionnaire of “Specific
study.

A total of 7025 participants (3337 men and 1688 women) who
underwent general health checkups between January 2008 and
December 2008 were enrolled in the study. Participants’ ages
ranged from 18 to 67 years (mean 41.7 ±11.1 years). After
enrollment, the participants were followed up by general health
checkups every year. We excluded 2184 participants who were
already diagnosed with CKD (n = 545), lacked some laboratory
data (n = 194) and had missing data for health behaviors (n = 3) at
baseline. In addition, we excluded the participants who were not
followed up in 2009 (n = 1442). Overall, the current analysis
comprised 4841 participants (3686 men and 1155 women) with
complete data on all the health behaviors and general health
checkups. Among those participants, 673 were lost to follow up.
However, we had no information on the causes of losing to follow
up. The mean follow-up period was 2.7 ±0.7 years (range,
0.2–3.9), 12,926 person-years.

Data Collection and Measurements

Measurements. After an overnight fast, blood and urine samples
were obtained to measure blood levels of routine medical
checkup tests: The complete blood count was measured automatically
in a Sysmex XE 2100 equipment (Roche Diagnostics, Kobe,
Japan). Fasting plasma glucose (FPG), triglycerides (TG), creatinine
(Cr) and low-density lipoprotein (LDL) cholesterol were measured
enzymatically. High-density lipoprotein (HDLC) cholesterol
was measured using the precipitation method. Hemoglobin
HbAic was measured using the latex agglutination method.
Uric acid (UA) was measured using uricase/POD method, Liver
function tests including γ-glutamyltransferase (GGT), aspartate
aminotransferase (AST), alanine aminotransferase (ALT) were
measured using the LDH-UV method. Simple qualitative urinalyses
were performed with a dipstick on flesh, mid-stream urine
collection in the morning, as a single control test. Chemical
measurements were all performed at a local laboratory (Medic,
Hamamatsu, Japan). Systolic blood pressure (SBP) and diastolic
blood pressure (DBP) were measured with the participants in a
sitting position. Height and body weight were measured with the
participants wearing lightweight clothing. WC was measured at
navel level in a standing position with light expiration.

Questionnaire interview. Participants were all required to
fill out a self-administered standardized questionnaire of “Specific
Health Checkups” in Japan, which included information about
lifestyle factors and medical history, including smoking status
(never, former or current smoker), alcohol drinking behavior (non/
rare, sometimes, everyday), regular exercise habit (exercising at
least 2 days/week, at least 30 minutes) and antihypertensive,
antidiabetic, antidyslipidemic and antihyperuricemic medications.

Three health behaviors – smoking status, alcohol intake and
regular exercise – were selected as study variables from self-
administered questionnaires.

Definitions

BMI was calculated as weight in kilograms divided by the
square of height in meters. Estimated glomerular filtration rate
(eGFR) was calculated as eGFR (mL/min/1.73 m²) = 194 × Crt
−1.094 × age −0.287 in men, and 194 × creatinine −1.094 × age
−0.287 × 0.739 in women according to the criteria of the Japanese
Society of Nephrology [20]. WheiR was calculated by dividing
the WC by body height. Low eGFR was defined as eGFR < 60 mL/
min/1.73 m². Proteinuria was defined as dipstick proteinuria
(≥1+). CKD was diagnosed on the basis of low eGFR and/or
proteinuria which were present in single test.

Follow-up and End Points

Participants were followed from the starting point until
December 31, 2011. The primary end point of this analysis was an
incidence of new CKD. Study participation was considered to
be complete if the participant had an occurrence of the primary
end point, was unable to be followed further because of loss of
follow-up, or had been followed through at least to December 31,
2011. The exposure time was calculated as the time between the
first visit to our institution and the point of either incidence of new
CKD or the date of the last study visit if that came first.

Statistical Analysis

All the data were expressed as the mean ± standard deviation
(SD) (parametrically distributed values) or median (interquartile
range) (non-parametrically distributed values) of the indicated
numbers. We divided the study population into gender-adjusted
quartiles of the distribution of WheiR. Differences among the
quartiles of WheiR were examined by one-way analyses of
variance (ANOVA) (parametrically distributed values) or
Kruskal-Wallis test (non-parametrically distributed values). The polynomial
contrast test and Kendall tau rank correlation coefficient
(Kendall’s tau-b) were used for trend analysis of numerical and
categorical variables. Categorical variables were compared among
the quartiles of WheiR by the chi-square test. Cox proportional-
hazards models were used to calculate hazard ratios and 95%
confidence intervals (CI) for the comparison of event rates while
controlling for potential confounders. The potential confounders were
selected from clinical variables and lifestyle factors associated
with CKD (Table 1). Receiver operating characteristic (ROC)
analyses were used to compare the predictive function of different
methods in identifying individuals with Obesity, and Hanley-
McNeil test was used to examine difference between area under
the curves (AUCs). A p-value < 0.05 was regarded as statistically
significant. The computations were performed using SPSS
programs (version 11.0 J; SPSS Inc., Chicago, IL, USA).

Results

Baseline Clinical Characteristics

The upper limits of the lowest (Q1), second (Q2), and third
quartiles of WheiR (Q3) were set at 0.44, 0.47 and 0.50 for males,
and 0.43, 0.46 and 0.50 for females, respectively. The mean values
for quartiles Q1, Q2, Q3 and Q4 of WheiR were 0.41 ±0.02,
0.46 ±0.01, 0.49 ±0.01 and 0.34 ±0.03 for males, and 0.41 ±0.02,
0.43 ±0.01, 0.48 ±0.01 and 0.55 ±0.05 for females, respectively.

Tables 2 and 3 show the participants’ baseline demographic and
clinical characteristics and health behaviors. There were signifi-
cant associations between WheiR and age, body weight, BMI,
Furthermore, significant positive trends for quartiles of WheiR were found for body weight, BMI, SBP, DBP, ALT, LDL cholesterol, HDL cholesterol, FPG, HbA1c, UA, RBC, Hct, Hb, Plt and WBC, while significant negative trends were shown for HDL cholesterol and eGFR (all p < 0.001 with the polynomial contrast test). As shown in Table 3, increasing WheiR was associated with higher

![Image of Table 1](image1)

**Table 1. Definitions of potential confounders selected from clinical variables and lifestyle factors associated with CKD.**

| Blood pressure >140/<90 mmHg and/or antihypertensives use |
| Hypertension |
| Diabetes mellitus | HbA1c ≥6.5%, and/or FPG ≥126 mg/dL and/or antidiabetes use |
| Increased LDL cholesterol | LDL cholesterol ≥140 mg/dL and/or antidyslipidemics use |
| Decreased HDL cholesterol | HDL cholesterol < 40 mg/dL (in men), < 50 mg/dL (in women) |
| Hypertriglyceridemia | TG ≥150 mg/dL |
| Hyperuricemia | UA ≥7.0 mg/dL and/or antihyperuricemics use |
| Preserved eGFR | eGFR ≥80 ml/min/1.73 m² |
| eGFR ≤60 ml/min/1.73 m² and/or antihypertensives use |
| eGFR ≤30 ml/min/1.73 m² and/or antihypertensives use |

**Table 2. Baseline Characteristics of the Study Participants.**

| Participants, n | Q1 1210 | Q2 1210 | Q3 1211 | Q4 1210 | p value |
|-----------------|---------|---------|---------|---------|---------|
| Age, median (interquartile range) (year) | 34 (18–67) | 40 (18–66) | 44 (18–63) | 49 (18–67) | <0.001 |
| Male gender | 922 (76.2%) | 921 (76.1%) | 922 (76.1%) | 921 (76.1%) | 1.000 |
| Height (cm) | 168.7 ± 7.9 | 167.5 ± 7.8 | 166.7 ± 7.6 | 165.1 ± 8.6 | <0.001 |
| Body weight (kg) | 54.7 ± 7.7 | 59.2 ± 8.8 | 62.8 ± 9.1 | 70.5 ± 12.6 | <0.001 |
| Body Mass Index (kg/m²) | 19.1 ± 5.5 | 20.9 ± 7.7 | 22.4 ± 18.8 | 25.6 ± 31.1 | <0.001 |
| Systolic blood pressure (mmHg) | 109.9 ± 11.4 | 113.1 ± 12.6 | 116.1 ± 13.4 | 120.7 ± 13.8 | <0.001 |
| Diastolic Blood Pressure (mmHg) | 68.1 ± 8.9 | 71.2 ± 9.8 | 73.6 ± 10.1 | 76.9 ± 10.1 | <0.001 |
| Aspartate aminotransferase (IU/L) | 20.9 ± 7.8 | 21.6 ± 7.0 | 22.5 ± 8.1 | 26.0 ± 14.4 | <0.001 |
| Alanine aminotransferase (IU/L) | 15 ± (3–135) | 18 (4–107) | 20 (5–165) | 25 (5–282) | <0.001 |
| Gamma glutamyltransferase (IU/L) | 20 ± (7–381) | 23 (7–539) | 26 (7–523) | 34 ± (7–521) | <0.001 |
| LDL Cholesterol (mg/dL) | 101.6 ± 25.5 | 115.0 ± 28.4 | 122.6 ± 29.5 | 132.2 ± 30.2 | <0.001 |
| Triglyceride (mg/dL) | 63 (22–424) | 78 (25–613) | 90 (23–512) | 111 (26–1155) | <0.001 |
| HDL-cholesterol (mg/dL) | 70.7 ± 16.7 | 87.1 ± 17.3 | 93.2 ± 16.7 | 98.0 ± 15.5 | <0.001 |
| Creatinine (mg/dL) | 0.82 ± 0.13 | 0.82 ± 0.14 | 0.82 ± 0.14 | 0.81 ± 0.13 | 0.057 |
| eGFR (ml/min/1.73 m²) | 83.2 ± 12.3 | 80.3 ± 12.6 | 78.2 ± 12.6 | 78.3 ± 12.2 | <0.001 |
| Fasting Plasma Glucose (mg/dL) | 94.2 ± 11.0 | 97.3 ± 16.1 | 98.5 ± 12.1 | 104.3 ± 20.3 | <0.001 |
| HbA1c (%) | 5.2 ± 0.4 | 5.3 ± 0.5 | 5.3 ± 0.5 | 5.5 ± 0.7 | <0.001 |
| Uric Acid (mg/dL) | 5.3 ± 1.2 | 5.5 ± 1.2 | 5.7 ± 1.3 | 5.9 ± 1.4 | <0.001 |
| Red blood cell count (10⁶/µL) | 484.3 ± 41.1 | 485.4 ± 42.6 | 488.9 ± 41.7 | 498.4 ± 41.3 | <0.001 |
| Hemoglobin (g/dL) | 14.5 ± 1.4 | 14.6 ± 1.4 | 14.6 ± 1.5 | 15.0 ± 1.5 | <0.001 |
| Male | 15.0 ± 1.0 | 15.2 ± 0.9 | 15.2 ± 1.0 | 15.6 ± 1.0 | <0.001 |
| Female | 12.8 ± 1.0 | 12.8 ± 1.2 | 12.7 ± 1.4 | 13.0 ± 1.4 | 0.032 |
| Hematocrit (%) | 43.3 ± 5.6 | 44.2 ± 5.7 | 44.3 ± 5.9 | 45.1 ± 3.9 | <0.001 |
| Platelets (10⁶/µL) | 23.9 ± 4.9 | 24.8 ± 5.2 | 25.0 ± 5.4 | 25.7 ± 6.1 | <0.001 |
| Leukocyte count (10⁹/L) | 5.6 ± 1.5 | 5.9 ± 1.5 | 5.1 ± 1.5 | 4.6 ± 1.7 | <0.001 |

**a** Data are expressed as n (%) or mean ± SD or median (interquartile range)

Q1, lowest quartiles; Q2, second quartiles; Q3, third quartiles; Q4, quartiles; HDL cholesterol, high-density lipoprotein cholesterol; LDL cholesterol, low-density lipoprotein cholesterol; eGFR, estimated glomerular filtration rate; HbA1c, hemoglobin A1c

doi:10.1371/journal.pone.0088873.t001
The Incidence of CKD in Relation to Quartiles of WheiR

A total of 384 (7.9%) participants including 300 men and 84 women received a new diagnosis of CKD during the study period, and 45, 79, 122 and 138 diagnoses were received in Q1, Q2, Q3 and Q4 of WheiR, respectively. The overall incidence of CKD was 29.7 per 1000 person-years. A graded relationship existed between WheiR and the incidence of CKD (Table 4).

In the unadjusted analysis, Cox proportional-hazards models revealed that the risk of CKD rose with each increasing quartile of WheiR. In a test for interaction between the quartiles of WheiR and follow-up time, there was no violation of the proportional-hazards assumption. In the multivariable analysis, the significant graded association between WheiR and the hazards ratio for CKD persisted after adjustment for age, gender, smoking status, alcohol drinking behavior, regular exercise, hypertension, increased LDL cholesterol, decreased HDL cholesterol, hypertriglyceridemia, hyperuricemia, urine occult blood and hemoglobin, this significant graded association between re-classified WheiR, respectively. After adjustment for age, gender, smoking status, alcohol drinking behavior, regular exercise, hypertension, increased LDL cholesterol, decreased HDL cholesterol, hypertriglyceridemia, hyperuricemia, urine occult blood and hemoglobin, this significant graded association between re-classified WheiR and the hazards ratio for CKD persisted (adjusted HR (95%CI); 1.00 (reference), 0.71 (0.21, 2.37, p = 0.575), 0.81 (0.25, 2.59, p = 0.721) and 2.12 (0.73, 6.16, p = 0.363) though the quartiles of re-classified WheiR, respectively.

The Incidence of Low eGFR and Proteinuria in Relation to Quartiles of WheiR

Table 5 shows the unadjusted and adjusted hazard ratios for low eGFR and proteinuria. In the unadjusted model, there was a significant graded association between WheiR and the incidence of both low eGFR and proteinuria, and these relationships persisted after adjustment for age, gender, smoking status, alcohol drinking behavior, regular exercise, hypertension, increased LDL cholesterol, decreased HDL cholesterol, hypertriglyceridemia, hyperuricemia, urine occult blood, hemoglobin and preserved eGFR at baseline. After further adjustment for BMI, WheiR associated with the incidence of neither proteinuria nor low eGFR.

### Table 3. Clinical Characteristics of the Study Participants

|                  | Q1       | Q2       | Q3       | Q4       | p value |
|------------------|----------|----------|----------|----------|---------|
| Urine occult blood | 55 (4.5%)| 61 (5.0%)| 44 (3.6%)| 59 (4.9%)| 0.345   |
| Hypertension     | 34 (2.8%)| 66 (5.5%)| 105 (8.7%)| 221 (18.3%)| <0.001  |
| Diabetes mellitus| 9 (0.7%) | 28 (2.3%)| 24 (2.0%)| 102 (10.8%)| <0.001  |
| Increased LDL cholesterol | 104 (8.6%)| 229 (18.9%)| 329 (27.2%)| 482 (39.8%)| <0.001  |
| Decreased HDL cholesterol | 28 (2.3%)| 36 (3.0%)| 59 (4.9%)| 104 (8.6%)| <0.001  |
| Hypertriglyceridemia | 29 (2.4%)| 128 (10.6%)| 202 (16.7%)| 351 (29.0%)| <0.001  |
| Preserved eGFR | 684 (56.5%)| 538 (44.5%)| 473 (39.1%)| 435 (36.0%)| <0.001  |
| Hyperuricemia    | 1101 (91.5%)| 1039 (85.9%)| 999 (82.5%)| 924 (76.4%)| <0.001  |
| Smoking status   |          |          |          |          | <0.001  |
| Never smokers    | 747 (61.7%)| 681 (56.3%)| 652 (53.8%)| 645 (53.3%)|         |
| Current Smokers  | 288 (23.8%)| 328 (27.1%)| 307 (25.4%)| 297 (24.5%)| <0.001  |
| Alcohol drinking behavior |       |          |          |          | <0.001  |
| Non/Rare         | 523 (43.2%)| 438 (36.2%)| 450 (37.2%)| 507 (41.9%)|         |
| Sometimes        | 488 (40.3%)| 473 (39.1%)| 456 (37.7%)| 430 (35.5%)|         |
| Every day        | 199 (16.4%)| 299 (24.7%)| 305 (25.2%)| 273 (22.6%)|         |
| Regular exercise | 256 (21.2%)| 278 (23.0%)| 260 (21.5%)| 270 (22.3%)| 0.696   |

Data are expressed as n (%).

a Definitions of these confounding factors are shown in Table 1.

WheiR, waist to height ratio; Q1, lowest quartiles; Q2, second quartiles; Q3, third quartiles; Q4, quartiles; LDL cholesterol, low-density lipoprotein cholesterol; HDL cholesterol, High-density lipoprotein cholesterol; eGFR, estimated glomerular filtration rate.

doi:10.1371/journal.pone.0088873.t003
### Table 4. Incidence of CKD in Relation to Quartiles of Waist to height ratio (WheiR).

| Quartile of WheiR | Incidence (/1000 person-years) | Unadjusted hazards ratio (95% CI) | p value | Adjusted hazards ratio (95% CI)\(^a\) | p value | Adjusted hazards ratio (95% CI)\(^b\) | p value |
|-------------------|-------------------------------|-----------------------------------|---------|---------------------------------------|---------|---------------------------------------|---------|
| Q1                | 1.37                          | (reference)                       |         | (reference)                           |         | (reference)                           |         |
| Q2                | 2.42                          | 1.75 (1.29, 2.52)                 | 0.003   | 1.23 (0.85, 1.78)                     | 0.275   | 0.99 (0.65, 0.66)                     | 0.963   |
| Q3                | 3.79                          | 2.78 (1.98, 3.91)                 | <0.001  | 1.59 (1.11, 2.26)                     | 0.011   | 1.15 (0.73, 1.80)                     | 0.547   |
| Q4                | 4.73                          | 3.31 (2.36, 4.65)                 | <0.001  | 1.62 (1.13, 2.32)                     | 0.009   | 1.14 (0.67, 1.91)                     | 0.633   |

p for trend <0.001

\(^a\) Adjusted for age, gender, smoking status, alcohol drinking behavior, regular exercise, hypertension, increased low-density lipoprotein cholesterol, decreased high-density lipoprotein cholesterol, hypertriglyceridemia, hyperuricemia, diabetes mellitus, urine occult blood, hemoglobin and preserved eGFR at baseline.

\(^b\) Adjusted for model 2 plus body mass index. Cox proportional-hazards models were used to calculate hazard ratios and 95% confidence intervals. Definitions of these confounding factors are shown in Table 1.

doi:10.1371/journal.pone.0088873.t004

### Table 5. Incidence of Proteinuria and Low eGFR in Relation to Quartiles of Waist to height ratio (WheiR).

| Quartile of WheiR | Unadjusted hazards ratio (95% CI) | p value | Adjusted hazards ratio (95% CI)\(^a\) | p value | Adjusted hazards ratio (95% CI)\(^b\) | p value |
|-------------------|-----------------------------------|---------|---------------------------------------|---------|---------------------------------------|---------|
| Low eGFR          | Q1 (reference)                    |         | (reference)                           |         | (reference)                           |         |
| Q2                | 2.00 (1.35, 2.94)                 | 0.001   | 1.33 (0.90, 1.98)                     | 0.152   | 1.05 (0.68, 1.34)                     | 0.82    |
| Q3                | 3.10 (2.15, 4.47)                 | <0.001  | 1.64 (1.12, 2.39)                     | 0.011   | 1.15 (0.71, 1.85)                     | 0.579   |
| Q4                | 3.36 (2.34, 4.85)                 | <0.001  | 1.54 (1.04, 2.27)                     | 0.03    | 1.04 (0.60, 1.81)                     | 0.881   |

p for trend <0.001

Proteinuria

| Quartile of WheiR | Unadjusted hazards ratio (95% CI) | p value | Adjusted hazards ratio (95% CI)\(^a\) | p value | Adjusted hazards ratio (95% CI)\(^b\) | p value |
|-------------------|-----------------------------------|---------|---------------------------------------|---------|---------------------------------------|---------|
| Q1                | (reference)                       |         | (reference)                           |         | (reference)                           |         |
| Q2                | 0.56 (0.16, 1.91)                 | 0.356   | 0.57 (0.18, 2.00)                     | 0.387   | 0.50 (0.13, 1.98)                     | 0.323   |
| Q3                | 1.16 (0.42, 3.19)                 | 0.778   | 1.21 (0.42, 3.49)                     | 0.724   | 0.89 (0.20, 3.95)                     | 0.88    |
| Q4                | 3.28 (1.40, 7.67)                 | 0.006   | 2.68 (1.01, 7.10)                     | 0.047   | 1.58 (0.29, 8.57)                     | 0.594   |

p for trend 0.001

\(^a\) Adjusted for age, gender, smoking status, alcohol drinking behavior, regular exercise, hypertension, increased low-density lipoprotein cholesterol, decreased high-density lipoprotein cholesterol, hypertriglyceridemia, hyperuricemia, diabetes mellitus, urine occult blood, hemoglobin and preserved eGFR at baseline.

\(^b\) Adjusted for model 2 plus body mass index. Cox proportional-hazards models were used to calculate hazard ratios and 95% confidence intervals. Definitions of these confounding factors are shown in Table 1.

doi:10.1371/journal.pone.0088873.t005
Surrogate Maker of Obesity

Comparison of the Predictive Values of CKD in Each Incidence of CKD and Quartiles of WheiR

Gender Differences in the Relationship between the Incidence of CKD and Quartiles of WheiR

We also investigated the association between gender, WheiR and the incidence of CKD. Table 6 shows the unadjusted and adjusted hazard ratios for CKD for males and females. In the unadjusted analysis, a graded relationship existed between WheiR and the risk of CKD in both males and females. However, after adjusting for potential confounders including BMI, WheiR was significantly associated with the incidence of CKD in females, whereas it was not significant in males.

Comparison of the Predictive Values of CKD in Each Surrogate Maker of Obesity

We also investigated the relationship between other markers of obesity including WC and BMI, and the incidence of CKD. To assess these relations, we divided the study participants into gender-adjusted quartiles of the distribution of WC and BMI. Table 7 shows the unadjusted and adjusted hazard ratios for CKD in each surrogate marker. In the unadjusted analysis, a graded relationship existed between both WC and BMI, and the risk of CKD. In the multivariable analyses, the significant graded association between these markers and the hazards ratio for CKD persisted after adjustment for potential confounders.

We also investigated the association between gender, WC, BMI and the incidence of CKD. In the unadjusted analyses, a graded relationship existed between each WC and BMI, and the risk of CKD in both gender. However, after adjusting for potential confounders, WC was not associated with the incidence of CKD in males.

The Performance of the WheiR for Predicting CKD

Finally, we performed the ROC analyses to examine which surrogate markers of body fat including WheiR, WC and BMI were superior predictors of the incidence of CKD. As shown in figure 1A, The AUC of WheiR was higher than those of both WC and BMI (WheiR, WC and BMI: 0.628 (95% CI 0.601–0.655), 0.611 (0.584, 0.638), p = 0.015, and 0.607 (0.579, 0.635), p = 0.012, respectively). Figure 1B and 1C shows the gender difference of predicting values for the incidence of CKD.

Table 6. Incidence of CKD in Relation to Quartiles of Waist to height ratio (WheiR) Stratified by Gender.

| Gender | Quartile of WheiR | Unadjusted hazards ratio (95% CI) | p value | Adjusted hazards ratio (95% CI) | p value | Adjusted hazards ratio (95% CI) | p value |
|--------|------------------|----------------------------------|---------|--------------------------------|---------|--------------------------------|---------|
| Male   | Q1 (reference)   | 1.00                             |         | 1.00                            |         | 1.00                            |         |
|        | Q2 (0.966, 2.111)| 1.08                            | 0.081   | 0.95                           | 0.064   | 0.67                           | 0.003   |
|        | Q3 (1.52, 3.14)  | <0.001                          | 0.118   | 0.65                           | 0.126   | 0.70                           | 0.168   |
|        | Q4 (1.91, 3.90)  | <0.001                          | 1.25    | 0.70                           | 0.267   | 0.71                           | 0.267   |
| Male   | p for trend      | <0.001                          |         | 0.111                          |         | 0.746                          |         |
| Female | Q1 (reference)   | 1.00                             |         | 1.00                            |         | 1.00                            |         |
|        | Q2 (1.90, 2.163) | 0.003                           | 5.31    | 0.008                          | 5.06    | 0.011                          |         |
|        | Q3 (3.49, 37.36) | <0.001                          | 9.24    | <0.001                         | 8.12    | 0.001                          |         |
|        | Q4 (3.51, 36.42) | <0.001                          | 7.18    | 0.002                          | 5.77    | 0.015                          |         |
| Female | p for trend      | <0.001                          |         | 0.001                          |         | 0.041                          |         |

a Adjusted for age, smoking status, alcohol drinking behavior, regular exercise, hypertension, increased low-density lipoprotein cholesterol, decreased high-density lipoprotein cholesterol, hypertriglyceridemia, hyperuricemia, diabetes mellitus, urine occult blood, hemoglobin and preserved eGFR at baseline.

b (model 3) Adjusted for model 2 plus body mass index. Cox proportional-hazards models were used to calculate hazard ratios and 95% confidence intervals. Definitions of these confounding factors are shown in Table 1.

WheiR, waist to height ratio; CI, confidence interval; Q1, lowest quartiles; Q2, second quartiles; Q3, third quartiles; Q4, highest quartiles

doi:10.1371/journal.pone.0088873.t006

Discussion

In this study, we found that the WheiR was an independent predictor for the incidence of CKD in the Japanese workers who participated. A graded relationship existed between quartiles of WheiR and the incidence of CKD. Compared with the lowest quartile, the incidence of CKD was 1.6 times higher in the highest quartile. WheiR had a strong predictive value for the incidence of both proteinuria and low eGFR. However, these relationships were abolished after adjustment BMI. There was a significant gender difference in the relationship between CKD and WheiR. After subdivision according to gender, the relationship between WheiR and the incidence of CKD was statistically significant in the unadjusted model in both genders. However, after adjusting for potential confounders including BMI, WheiR was significantly associated with the incidence of CKD in females, whereas it was not significant in males.

It is well-established that overall and central obesity are associated with cardiovascular risk factors such as hyperglycemia, diabetes, hypertension, dyslipidemia and metabolic syndrome [21,22]. WheiR, WC and BMI could similarly predict cardiometabolic risk factors [22]. Most public health literature is focused on the use of BMI to identify obesity. However, BMI does not distinguish between muscle and fat, visceral and subcutaneous fat, or peripheral and central adiposity. A previous study indicated that WC strongly correlated with visceral fat as measured by computed tomography [23]. Furthermore, because height is also one of the factors that influences fat accumulation and distribution, WheiR might be a more accurate way to track fat distribution and accumulation than weight circumference [18]. Thus, we used WheiR as an index for central obesity.
Obesity and metabolic syndrome are known as independent risk factors for CKD [24,25]. In previous studies, obesity has been implicated in the development focal segmental glomerulosclerosis and glomerulomegaly [26,27]. Visceral adipose tissue secretes inflammatory cytokines such as interleukin-6 and tumor necrosis factor α, which are associated with both obesity-related glomerulopathy and metabolic syndrome [28–32]. It is not clear if it is central obesity or the related cardiometabolic risk factors that initiate renal injury. In the current study, the association between the WheiR and CKD remained robust even after adjusting for confounding factors, including cardiometabolic risk factors. This result suggested that the risk for CKD was not solely attributable to metabolic syndrome, which is consistent with a previous study that showed WheiR was significantly associated with CKD, independent of hypertension and diabetes [33].

In our results, WheiR was an independent predictor for the incidence of CKD in participants with eGFR < 80 mL/min/1.73 m², however, this association was not significant in participants with eGFR ≥ 80 mL/min/1.73 m². We speculated that this result was affected by inclusion of participants at different degree of proteinuria. Although several participants were diabetic, dyslipidemic and hypertensive in our study, we did not evaluate the microalbuminuria and had no information concerning the presence of proteinuria or kidney diseases without the results of self-administrated questionnaire before the study began. The lack of these data partially affected our results of the association between WheiR and the future appearance of a renal dysfunction. Our results indicated the WheiR was an independent risk factor for the incidence of both low eGFR and proteinuria. However, the endpoint for the incident of proteinuria might lack the statistical and biological power, because p values were at the threshold of significance. Dipstick urinalysis might not be a reliable screening method for proteinuria. Previous study reported that the sensitivity, specificity and positive and negative predictive values

Table 7. Comparison of the Predictive Values of CKD in Each Surrogate Maker of Obesity.

| Gender | Marker | Quartile of WheiR | Unadjusted hazards ratio (95% CI) | p value | Adjusted hazards ratio (95% CI)a | p value |
|--------|--------|------------------|----------------------------------|---------|-------------------------------|---------|
| Overall Waist circumference Q1 (reference) (reference) | Q2 1.91 (1.33, 2.73) | < 0.001 | 1.41 (0.98, 2.02) | 0.068 |
| | Q3 2.47 (1.75, 3.48) | < 0.001 | 1.47 (1.03, 2.09) | 0.033 |
| | Q4 3.06 (2.19, 4.30) | < 0.001 | 1.67 (1.16, 2.39) | 0.006 |
| | p for trend | < 0.001 | 1.09 | |
| Body mass index Q1 (reference) (reference) | Q2 2.08 (1.46, 2.97) | < 0.001 | 1.58 (1.10, 2.25) | 0.013 |
| | Q3 2.66 (1.88, 3.75) | < 0.001 | 1.80 (1.27, 2.57) | 0.001 |
| | Q4 2.90 (2.07, 4.08) | < 0.001 | 1.79 (1.25, 2.56) | 0.001 |
| | p for trend | < 0.001 | 1.09 | |
| Males Waist circumference Q1 (reference) (reference) | Q2 1.67 (1.12, 2.48) | 0.012 | 1.14 (0.77, 1.72) | 0.557 |
| | Q3 2.33 (1.61, 3.38) | < 0.001 | 1.34 (0.90, 1.97) | 0.139 |
| | Q4 2.57 (1.78, 3.73) | < 0.001 | 1.38 (0.92, 2.07) | 0.122 |
| | p for trend | < 0.001 | 1.09 | |
| Body mass index Q1 (reference) (reference) | Q2 2.25 (1.51, 3.35) | < 0.001 | 1.68 (1.12, 2.52) | 0.012 |
| | Q3 2.63 (1.78, 3.90) | < 0.001 | 1.78 (1.19, 2.67) | 0.005 |
| | Q4 2.82 (2.82, 4.15) | < 0.001 | 1.79 (1.18, 2.70) | 0.006 |
| | p for trend | < 0.001 | 1.09 | |
| Females Waist circumference Q1 (reference) (reference) | Q2 3.45 (1.40, 8.47) | 0.007 | 2.99 (1.21, 7.39) | 0.018 |
| | Q3 3.29 (1.31, 8.24) | 0.011 | 2.43 (0.96, 6.15) | 0.061 |
| | Q4 6.27 (2.60, 14.89) | < 0.001 | 3.93 (1.61, 9.60) | 0.003 |
| | p for trend | < 0.001 | 1.09 | |
| Body mass index Q1 (reference) (reference) | Q2 1.47 (0.66, 3.28) | 0.344 | 1.39 (0.60, 3.00) | 0.481 |
| | Q3 2.75 (1.34, 5.63) | 0.006 | 2.33 (1.12, 4.86) | 0.023 |
| | Q4 3.19 (1.56, 6.35) | 0.001 | 2.32 (1.11, 4.87) | 0.025 |
| | p for trend | < 0.001 | 1.09 | |

a Adjusted for age, smoking status, alcohol drinking behavior, regular exercise, hypertension, increased low-density lipoprotein cholesterol, decreased high-density lipoprotein cholesterol, hypertriglyceridemia, hyperuricemia, diabetes mellitus, urine occult blood, hemoglobin and preserved eGFR at baseline. Cox proportional-hazards models were used to calculate hazard ratios and 95% confidence intervals. Definitions of these confounding factors are shown in Table 1.

CI, confidence interval; Q1, lowest quartiles; Q2, second quartiles; Q3, third quartiles; Q4, highest quartiles.

doi:10.1371/journal.pone.0088873.t007
of the dipstick test for detection of protein were 80.0%, 95.0%, 22.2% and 99.6% [34].

We found gender differences in the association between WheiR and the risk of CKD. Previous studies have reported that WheiR was more frequently associated with renal injury in females than males [33,35]. Although it remains unclear how gender influences the correlation between WheiR and CKD, several hypotheses have proposed. First, the lack of an association between the WheiR and CKD in males suggested that the risk factors might be different between males and females and that factors other than central obesity might be more important in males. Second, anemia might contribute to the progression of CKD, especially in females. Because hypoxia can be exacerbated by lower hemoglobin levels, anemia might have a role in the progression of CKD. In our participants, the hemoglobin levels were lower values in females than those in males through the quartiles of WheiR (Table 2). However, in our study, after adjustment for potential confounders including hemoglobin, WheiR was still an independent predictor for CKD. Finally, another possibility is that sex hormones might have a role in the interaction with this association. Further studies are necessary to elucidate the mechanism by which gender differences have an influence on these relationships.

In this study, we also evaluated the predictive values of other markers of obesity. Our results indicated that BMI also had a strong predictive value as same as WheiR (Table 4, 7). Interestingly, as shown in Table 6, WheiR was still an independent risk factor for the incidence of CKD after adjustment for potential confounder including BMI in only females. This finding supported the gender differences in the association between WheiR and the risk of CKD.

The current study has several limitations. First, we did not evaluate the changes in WheiR in individual participants during the study period. Second, self-reported information regarding daily regular exercise, alcohol intake and smoking status is prone to underreporting, and misreporting could be a source of bias. Third, we did not investigate whether participants underwent kidney biopsy, thus, the etiology of the CKD associated with WheiR was not identified. However, the proportion of hypertensive and diabetes in participant with developing CKD were higher than those in participants without developing CKD (data not shown). These associations suggested that some of the etiology of CKD might be glomerular sclerosis and/or diabetic nephropathy. Fourth, we could not completely exclude the participants who had any infections, malignacies or other peculiar disorders, because our self-administered standardized questionnaire did not require

![Figure 1. Receiver operating characteristic analyses describing the predictive value of each surrogate marker of obesity. (A) The area under the receiver operating characteristic curve (AUC) of waist to height ratio (WheiR), body mass index (BMI) and waist circumference (WC) were calculated as 0.628 (95% Confidence interval; 0.601–0.655), 0.611 (0.584, 0.638), and 0.607 (0.579, 0.635), respectively in all study participants. (B) and (C) Participants were stratified by gender. The AUCs of WheiR, BMI and WC were 0.619 (0.587, 0.650), 0.604 (0.572, 0.635), and 0.604 (0.572, 0.636), respectively, in male gender (B), and 0.660 (0.610, 0.710), 0.656 (0.604, 0.708), and 0.628 (0.572, 0.665), respectively, in female gender (C). doi:10.1371/journal.pone.0088873.g001](#)
filling out about these information. Finally, there might be selection bias related to the healthy worker effect.

In conclusion, WheiR, which is one of the markers of central obesity, has the potential to be a useful surrogate marker for predicting the future development of CKD. There was a significant gender difference in the relationship between CKD and WheiR. Further study is needed to clarify the efficacy of interventions reducing the WheiR to decline the risk of CKD.

Acknowledgments

We are indebted to Dr. Sachiko Miyakawa and Dr. Aiko Hakamata for editorial help. The authors thank the study participants for their time and dedication to the study.

Author Contributions

Conceived and designed the experiments: KO. Performed the experiments: KO MY IM YM AU. Analyzed the data: KO. Wrote the paper: KO. Revised the manuscript: AU HW.

References

1. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY (2004) Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351: 1296–1305.
2. Hallan SI, Dahl K, Olsen CM, Grootendorst DC, Aasberg A, et al. (2006) Screening strategies for chronic kidney disease in the general population: follow-up of cross-sectional health survey. BMJ 335: 1047.
3. Hooi LS, Ong LM, Ahmad G, Bavanandan S, Ahmad NA, et al. (2013) A population-based study measuring the prevalence of chronic kidney disease among adults in West Malaysia. Kidney Int 84: 1034–1040.
4. Kearns B, Gallaghér H, de Luissign S (2013) Predicting the prevalence of chronic kidney disease in the English population: a cross-sectional study. BMC Nephrol 14: 49–59.
5. Zhang L, Wang F, Wang L, Wang W, Liu B, et al. (2012) Prevalence of chronic kidney disease in China: a cross-sectional survey. Lancet 379: 815–822.
6. Imai E, Horio M, Watanabe T, Iseki K, Yamagata N, et al. (2009) Prevalence of chronic kidney disease in the Japanese general population. Clin Exp Nephrol 13: 621–630.
7. Coren J, Selvin E, Stevens LA, Manzi J, Kusek JW, et al. (2007) Prevalence of chronic kidney disease in the United States. JAMA 298: 2038–2047.
8. Nagata M, Ninomiya T, Doi Y, Yonemoto K, Kubo M, et al. (2010) Trends in the prevalence of chronic kidney disease and its risk factors in a general Japanese population: the Hisayama Study. Nephrol Dial Transplant 25: 2557–2564.
9. Grams ME, Juraschek SP, Selvin E, Foster MC, Inker LA, et al. (2013) Detection of chronic kidney disease in patients with or at increased risk of cardiovascular disease: a science advisory from the American Heart Association Kidney And Cardiovascular Disease Council; the Councils on High Blood Pressure Research, Cardiovascular Disease in the Young, and Epidemiology and Prevention; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: developed in collaboration with the National Kidney Foundation. Circulation 114: 1083–1087.
10. Heerink NJ, de Zeeuw D (2013) Novel drugs and intervention strategies for the treatment of chronic kidney disease. Br J Clin Pharmacol 76: 536–550.
11. Govindarajan G, Whaley-Connell A, Mugo M, Stump C, Sowers JR (2005) The treatment of chronic kidney disease in patients with or at increased risk of cardiovascular disease: insights from renal biopsy samples. Endocrinology 146: 440–447.
12. Chiba Y, Saitoh S, Takagi S, Ohnishi H, Katoh N, et al. (2007) Relationship between visceral fat and cardiovascular disease risk factors: the Tanno and Sobetsu study. Hypertens Res 30: 229–236.
13. Liu Y, Tong G, Tong W, Lu L, Qin X (2011) Can body mass index, waist circumference, waist-hip ratio and waist-height ratio predict the presence of multiple metabolic risk factors in Chinese subjects? BMC Public Health 11: 31–35.
14. Sonches FM, Avesani CM, Kamimura MA, Lemos MM, Axelsen J, et al. (2008) Waist circumference and visceral fat in CKD: a cross-sectional study. Am J Kidney Dis 52: 66–73.
15. Hallan SI, Dahl K, Olsen CM, Grootendorst DC, Aasberg A, et al. (2006) Screening strategies for chronic kidney disease in the general population: follow-up of cross-sectional health survey. BMJ 335: 1047.
16. Katzmarzyk PT, Heymsfield SB, Bouchard C (2013) Clinical utility of visceral abdominal visceral fat, and cardiometabolic risk factors: the Jackson Heart Study. Obesity (Silver Spring) 14: 336–341.
17. Ashwell M, Gunn P, Gibson S (2012) Waist-to-height ratio is a better screening tool than waist circumference and BMI for adult cardiometabolic risk factors: systematic review and meta-analysis. Obes Rev 13: 275–286.
18. Brosius FC 3rd, Hostetter TH, Kelepouris E, Mitsnefes MM, Moe SM, et al. (2006) Detection of chronic kidney disease in patients with or at increased risk of cardiovascular disease: a science advisory from the American Heart Association Kidney And Cardiovascular Disease Council; the Councils on High Blood Pressure Research, Cardiovascular Disease in the Young, and Epidemiology and Prevention; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: developed in collaboration with the National Kidney Foundation. Circulation 114: 1083–1087.
19. Heerink NJ, de Zeeuw D (2013) Novel drugs and intervention strategies for the treatment of chronic kidney disease. Br J Clin Pharmacol 76: 536–550.
20. Imai E, Horio M, Watanabe T, Iseki K, Yamagata N, et al. (2009) Prevalence of chronic kidney disease in the Japanese general population. Clin Exp Nephrol 13: 621–630.
21. Coren J, Selvin E, Stevens LA, Manzi J, Kusek JW, et al. (2007) Prevalence of chronic kidney disease in the United States. JAMA 298: 2038–2047.
22. Nagata M, Ninomiya T, Doi Y, Yonemoto K, Kubo M, et al. (2010) Trends in the prevalence of chronic kidney disease and its risk factors in a general Japanese population: the Hisayama Study. Nephrol Dial Transplant 25: 2557–2564.
23. Grams ME, Juraschek SP, Selvin E, Foster MC, Inker LA, et al. (2013) Detection of chronic kidney disease in patients with or at increased risk of cardiovascular disease: a science advisory from the American Heart Association Kidney And Cardiovascular Disease Council; the Councils on High Blood Pressure Research, Cardiovascular Disease in the Young, and Epidemiology and Prevention; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: developed in collaboration with the National Kidney Foundation. Circulation 114: 1083–1087.
24. Heerink NJ, de Zeeuw D (2013) Novel drugs and intervention strategies for the treatment of chronic kidney disease. Br J Clin Pharmacol 76: 536–550.
25. Govindarajan G, Whaley-Connell A, Mugo M, Stump C, Sowers JR (2005) The cardiometabolic syndrome as a cardiovascular risk factor. Am J Med Sci 330: 311–318.
26. Kok JL, Katanzarzyk PT, Richman MZ, Church TS, Blair SN, et al. (2006) Visceral fat is an independent predictor of all-cause mortality in men. Obesity (Silver Spring) 14: 336–341.
27. Matsuo S, Imai E, Horio M, Yauuda Y, Tomita K, et al. (2009) Revised the manuscript: AU HW.
28. Weisteen JR, Kempson RL, Elderfield FL, Swanon RS (1974) The nephritic syndrome: a complication of massive obesity. Ann Intern Med 81: 440–447.
29. Wu Y, Liu Z, Xiang Z, Zeng C, Chen Z, et al. (2006) Obesity-related glomerulopathy: insights from gene expression profiles of the glomeruli derived from renal biopsy samples. Endocrinology 147: 44–50.
30. Wise BR (2004) The inflammatory syndrome: the role of adipose tissue cytokines in metabolic disorders linked to obesity. J Am Soc Nephrol 15: 2792–2800.
31. Hotamisligil GS, Spiegelman BM (1995) Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 95: 2409–2415.
32. Pickup JC, Mattlock MB, Clunsey GD, Burt D (1997) NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 40: 1296–1292.
33. Lin CH, Chou CY, Liu CC, Huang CC, Liu CS, et al. (2007) Waist-to-height ratio is the best index of obesity in association with chronic kidney disease. Nutrition 23: 788–793.
34. Zamanud B (2009) Accuracy of dipstick urinalysis as a screening method for detection of glucose, protein, nitrites and blood. East Mediterr Health J 15: 1323–1328.
35. Tseng CH (2005) Waist-to-height ratio is independently and better associated with urinary albumin excretion rate than waist circumference or waist-to-hip ratio in chinese adult type 2 diabetic women but not men. Diabetes Care 28: 2249–2251.